Warszawski Uniwrsytet Medyczny

ABM11 Assessment of the incidence of persistent pulmonary hypertension of the newborn in a group of newborns born between 32 and 42 weeks of gestation treated with salbutamol -The primary objective of the clinical trial will be to assess the incidence of PPHN (PPHN-persistent pulmonary hypertension of the newborn) defined as the need for ventilation with FiO2 > 0.50 and echocardiographic signs of increased pulmonary pressure (left-right or bidirectional shunt through a patent ductus arteriosus) or the need for ventilation with FiO2 > 0.50 and a difference in pre- and post-ductal saturation > 20%) in the treatment of respiratory failure in a group of newborns born between 32 and 41 weeks of gestation. The secondary objectives will be to assess the modified Silverman scale, hereinafter referred to as the "TTN scale" in comparison to the concentration of oxygen used during ventilation and the intervention used, and to assess the parameters of the acid-base balance test: pH, carbon dioxide tension (pCO2), base deficiency (BE) in the compared groups. The study was planned as a prospective, multicenter, double-blind, randomized, placebo-controlled study.

ABM03 A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC). The aim of the presented IMPROVE-MC study is to evaluate the efficacy and safety of 12 months of immunosuppressive treatment with prednisone and azathioprine compared to placebo, in combination with standard therapy, in patients with virus-negative inflammatory cardiomyopathy/cardiomyopathy. An additional goal of the project is to create a diagnostic and therapeutic protocol ready for implementation in Polish and global healthcare systems, enabling modification of treatment guidelines for inflammatory cardiomyopathy.

Other program services